{"entity":{"id":"nct07774754","kind":"trial","name":"Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial","aka":["RADIANT"],"tldr":"A phase 2 trial of sintilimab and capecitabine in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.","summary":"Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial is a phase 2, interventional study registered as NCT07774754 by Sun Yat-sen University, with a registry enrolment figure of 18 participants, started 2026-09-01 and due to reach its primary completion in 2028-01-01. Interventions recorded: Drug：sintilimab; Drug：Capecitabine; Drug：Suvemcitug; Radiation: Neoadjuvant Radiotherapy. Conditions listed: Rectal Cancer. Primary outcome: Serious Adverse Effects of Neoadjuvant Therapy. Colorectal eligibility wording from the registry: \"3\\) Histologically confirmed rectal adenocarcinoma;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07774754","url":"https://clinicaltrials.gov/study/NCT07774754"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt"],"targets":[],"drugs":["sintilimab","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07774754","phase":"2","setting":"Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial","sponsor":"Sun Yat-sen University","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07774754/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}